Simultaneous treatment with anti-PD1 and anti-OX40 cancer therapies may have detrimen
 

Concurrent administration of the T-cell stimulating anti-OX40 antibody and the immune checkpoint inhibitor anti-PD1 antibody attenuated the effect of anti-OX40 and resulted in poor treatment outcomes in mice.

More...